NO885352L - Vannloeselige camptothecin-analoger. - Google Patents

Vannloeselige camptothecin-analoger.

Info

Publication number
NO885352L
NO885352L NO88885352A NO885352A NO885352L NO 885352 L NO885352 L NO 885352L NO 88885352 A NO88885352 A NO 88885352A NO 885352 A NO885352 A NO 885352A NO 885352 L NO885352 L NO 885352L
Authority
NO
Norway
Prior art keywords
alkyl
hydrogen
ch2nh2
formyl
cyano
Prior art date
Application number
NO88885352A
Other languages
English (en)
Other versions
NO170487C (no
NO170487B (no
NO885352D0 (no
Inventor
Jeffrey Charles Boehm
Sidney Michael Hecht
Kenneth George Holden
Randall Keith Johnson
William Dennis Kingsbury
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of NO885352D0 publication Critical patent/NO885352D0/no
Publication of NO885352L publication Critical patent/NO885352L/no
Priority to NO912386A priority Critical patent/NO172391C/no
Publication of NO170487B publication Critical patent/NO170487B/no
Publication of NO170487C publication Critical patent/NO170487C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Semiconductor Lasers (AREA)
NO885352A 1987-12-01 1988-11-30 Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger NO170487C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO912386A NO172391C (no) 1987-12-01 1991-06-19 Mellomprodukt for fremstilling av vannloeselige camptothecin-analoger

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12714887A 1987-12-01 1987-12-01

Publications (4)

Publication Number Publication Date
NO885352D0 NO885352D0 (no) 1988-11-30
NO885352L true NO885352L (no) 1989-06-02
NO170487B NO170487B (no) 1992-07-13
NO170487C NO170487C (no) 1992-10-21

Family

ID=22428545

Family Applications (2)

Application Number Title Priority Date Filing Date
NO885352A NO170487C (no) 1987-12-01 1988-11-30 Analogifremgangsmaate til fremstilling av terapeutisk aktive vannloeselige camptothecin-analoger
NO1998003C NO1998003I1 (no) 1987-12-01 1998-01-15 Topotecan

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1998003C NO1998003I1 (no) 1987-12-01 1998-01-15 Topotecan

Country Status (25)

Country Link
US (1) US5004758A (no)
EP (1) EP0321122B1 (no)
JP (1) JPH0633268B2 (no)
KR (1) KR930009357B1 (no)
CN (3) CN1027265C (no)
AT (1) ATE143368T1 (no)
AU (1) AU612735B2 (no)
CA (1) CA1308102C (no)
CY (1) CY2017A (no)
DE (2) DE3855575T2 (no)
DK (1) DK173034B1 (no)
ES (1) ES2094721T3 (no)
FI (1) FI89923C (no)
GR (1) GR3021990T3 (no)
HK (1) HK81097A (no)
IE (1) IE74873B1 (no)
IL (1) IL88517A (no)
LU (2) LU90026I2 (no)
MX (1) MX9203744A (no)
NL (1) NL970017I2 (no)
NO (2) NO170487C (no)
NZ (1) NZ227124A (no)
PT (1) PT89111B (no)
SG (1) SG66254A1 (no)
ZA (1) ZA888938B (no)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
JP2684104B2 (ja) * 1990-02-09 1997-12-03 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2848958B2 (ja) * 1990-09-28 1999-01-20 スミスクライン・ビーチャム・コーポレイション 水溶性カンプトテシン類似体、方法および手段
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
DK0572549T3 (da) * 1991-02-21 2003-01-06 Smithkline Beecham Corp Behandling af ikke-småcellet lungecarcinom
ATE444755T1 (de) * 1991-02-21 2009-10-15 Smithkline Beecham Corp Verwendung von topotecan zur herstellung eines medikaments zur verwendung in der behandlung von ovarialkrebs
AU664172B2 (en) * 1991-02-21 1995-11-09 Smithkline Beecham Corporation Treatment of esophageal cancer
US5559235A (en) * 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
WO1993009782A1 (en) * 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
AU2394392A (en) * 1991-12-10 1993-07-19 Smithkline Beecham Corporation Treatment of colorectal cancer
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
EP0655919A4 (en) * 1992-08-21 1995-10-18 Dana Farber Cancer Inst Inc TREATING VIRUS INFECTIONS IN HUMANS.
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5674872A (en) * 1993-08-20 1997-10-07 Smithkline Beecham Corporation Treatment of ovarian cancer
CA2174350A1 (en) * 1993-10-20 1995-04-27 Richard B. Greenwald 2'- and/or 7- substituted taxoids
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
WO1995029677A1 (en) * 1994-04-28 1995-11-09 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin or 7-ethyl camptothecin
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US6504029B1 (en) * 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) * 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5942386A (en) * 1995-06-07 1999-08-24 Thomas Jefferson University Anti-fungal agents and methods of identifying and using the same
WO1997019085A1 (en) * 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
IL127800A (en) * 1996-08-19 2005-11-20 Bionumerik Pharmaceuticals Inc Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them
US6013505A (en) 1996-10-08 2000-01-11 Smithkline Beecham Corporation Topoisomerase I
US5962303A (en) 1996-10-15 1999-10-05 Smithkline Beecham Corporation Topoisomerase III
US6025156A (en) * 1996-10-15 2000-02-15 Smithkline Beecham Corporation Topoisomerase III
US6559309B2 (en) 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
AU6272598A (en) * 1997-02-14 1998-09-08 Bionumerik Pharmaceuticals, Inc. Highly lipophilic camptothecin derivatives
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
KR100289860B1 (ko) * 1997-07-17 2001-05-15 나카무라 하사오 크로만의 제조 방법
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
NZ509859A (en) * 1998-08-05 2003-09-26 Aventis Pharma S Use of camptothecin derivatives, with reduced gastrointestinal toxicity
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
FR2801309B1 (fr) * 1999-11-18 2002-01-04 Adir Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
KR100717916B1 (ko) 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
IL155509A0 (en) 2000-10-27 2003-11-23 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2002040653A2 (en) * 2000-11-14 2002-05-23 Emerald Biostructures, Inc. Chrystal compositions comprising topoisomerase i
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
JP4509574B2 (ja) * 2002-03-26 2010-07-21 勤 鍵谷 癌化学治療改善剤
ITRM20020306A1 (it) * 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004055020A1 (en) * 2002-12-16 2004-07-01 Council Of Scientific And Industrial Research Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
JP4477510B2 (ja) * 2003-03-31 2010-06-09 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ １０−ヒドロキシ−４−（ｓ）カンプトテンシンからトポテカンを調製する方法
CN100406460C (zh) * 2003-11-10 2008-07-30 中国科学院上海药物研究所 喜树碱的新衍生物、制备方法和用途
AR046579A1 (es) * 2003-11-12 2005-12-14 Smithkline Beecham Corp Compuesto cristalino de topotecan, composicion farmaceutica que lo comprende, procedimiento para prepararlo y su uso para preparar dicha composicion farmaceutica
ATE507240T1 (de) * 2004-03-05 2011-05-15 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
CN1946421B (zh) 2004-04-27 2013-07-17 威尔斯达特生物制剂公司 使用病毒和喜树碱进行的癌症治疗
US20050267141A1 (en) 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
US7122700B2 (en) * 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
WO2012050591A1 (en) 2010-10-15 2012-04-19 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
US20080161251A1 (en) 2005-01-21 2008-07-03 Astex Therapeutics Limited Pharmaceutical Compounds
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
NZ562951A (en) * 2005-07-14 2011-09-30 Wellstat Biologics Corp Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination
KR20080068052A (ko) * 2005-10-10 2008-07-22 씨아이피엘에이 엘티디. 신규의 결정형
WO2007075492A1 (en) * 2005-12-16 2007-07-05 Sonus Pharmaceuticals, Inc. Lipophilic anticancer drug compounds
US7547785B2 (en) 2005-12-26 2009-06-16 Dr. Reddy's Laboratories Limited Process for preparing topotecan
WO2007085370A1 (en) * 2006-01-25 2007-08-02 Heidelberg Pharma Ag 9-(dimethylamino)-methyl-10-hydroxy-camptothecin lipidester derivatives
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
US20070259031A1 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7977483B2 (en) * 2007-04-11 2011-07-12 Scinopharm Taiwan, Ltd. Process for making topotecan
US20080255175A1 (en) * 2007-04-16 2008-10-16 Lam Marina K Anti-cancer agents, compositions and methods of treating cancers
WO2008130534A1 (en) * 2007-04-19 2008-10-30 Scinopharm Taiwan Ltd. Crystalline forms of topotecan hydrochloride and processes for making the same
US8026249B2 (en) * 2007-09-14 2011-09-27 Deutena Pharmaceuticals, Inc. Deuterium-enriched topotecan
ITMI20072268A1 (it) 2007-12-04 2009-06-05 Antibioticos Spa Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
CN102046634B (zh) * 2008-05-29 2013-04-24 日本迈科洛生物制药有限公司 喜树碱衍生物的制备方法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201026715A (en) * 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
JP6104504B2 (ja) * 2008-12-23 2017-03-29 ギリアド ファーマセット エルエルシー ヌクレオシド類似体
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
CL2011000716A1 (es) 2010-03-31 2012-04-20 Gilead Pharmasset Llc Formas cristalinas 1 6 de (s)-isopropil-2-(((s)-(((2r.3r.4r.5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro-3-hidroxi-4-metil tetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato; composicion y combinacion farmaceutica; y su uso para tratar una infeccion por el virus de la hepatitis c.
RU2447076C1 (ru) * 2010-12-09 2012-04-10 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения топотекана
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
EP2654754B1 (en) 2010-12-17 2016-12-21 Novartis AG Combination for treating osteosarcoma, rhabdomyosarcoma and neuroblastoma
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
US20130303560A1 (en) 2011-02-01 2013-11-14 Sunnybrook Research Institute Combination
JP6050822B2 (ja) 2011-10-03 2016-12-21 モレインクス，エービー ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用
PL235836B1 (pl) * 2012-10-25 2020-11-02 Inst Chemii Organicznej Polskiej Akademii Nauk Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
CN103113381B (zh) * 2013-02-26 2014-12-10 大连理工大学 系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
EP3250611B1 (en) 2015-01-26 2021-04-21 The University of Chicago Car t-cells recognizing cancer-specific il 13r-alpha2
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
CA2995029C (en) 2015-09-25 2022-10-25 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
SI3458052T1 (sl) * 2016-05-17 2020-04-30 Scandion Oncology A/S Kombinirano zdravljenje raka
MA49849A (fr) 2017-08-07 2020-06-17 Amgen Inc Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
SG11202109986TA (en) 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
JP2022530241A (ja) 2019-04-30 2022-06-28 インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤
WO2020242720A1 (en) 2019-05-02 2020-12-03 University Of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
EP3986441A1 (en) 2019-06-24 2022-04-27 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
EP4025206A1 (en) 2019-09-02 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating pax6- deficiency related disease
BR112022017064A2 (pt) * 2020-02-25 2022-11-16 Mediboston Inc Derivados da camptotecina e seus conjugados
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN116478174B (zh) * 2022-07-29 2025-09-16 杭州爱科瑞思生物医药有限公司 喜树碱衍生物及其制备方法和应用
CN116270641A (zh) * 2023-03-09 2023-06-23 兰州大学 喜树碱类衍生物在制备治疗膀胱癌药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4342776A (en) * 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58134095A (ja) * 1982-02-05 1983-08-10 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS59227884A (ja) * 1983-06-09 1984-12-21 Yakult Honsha Co Ltd 新規な７−ヒドロキシアルキルカンプトテシン誘導体
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4775759A (en) * 1984-11-27 1988-10-04 The United States Of America As Represented By The Department Of Health And Human Services Synthesis and utilization of 17-methyl and 17-cyclopropylmethyl-3,14-dihydroxy-4,5α-epoxy 6β-fluoromorphinans (foxy and cyclofoxy) as (18F)-labeled opioid ligands for position emission transaxial tomography (PETT)
US4820816A (en) * 1985-08-02 1989-04-11 President And Fellows Of Harvard College 3-trifuoromethylsulfonyloxy-substituted 1-carbacephalosporins as intermediates for antibiotics
JPH0615546B2 (ja) * 1986-02-24 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP3431931B2 (ja) * 1992-07-16 2003-07-28 旭電化工業株式会社 銅及び銅合金の表面処理方法

Also Published As

Publication number Publication date
AU2639488A (en) 1989-06-01
IE74873B1 (en) 1997-08-13
JPH01186893A (ja) 1989-07-26
LU90053I2 (fr) 1997-07-01
MX9203744A (es) 1992-09-01
EP0321122B1 (en) 1996-09-25
SG66254A1 (en) 1999-07-20
CN1027265C (zh) 1995-01-04
CN1034724A (zh) 1989-08-16
CN1037574C (zh) 1998-03-04
EP0321122A3 (en) 1990-12-27
DK173034B1 (da) 1999-11-29
DE3855575T2 (de) 1997-03-20
LU90026I2 (fr) 1997-04-22
FI885569A0 (fi) 1988-11-30
DE3855575D1 (de) 1996-10-31
CN1035380C (zh) 1997-07-09
ZA888938B (en) 1990-03-28
IE883576L (en) 1989-06-01
DK663688D0 (da) 1988-11-28
DE19775017I2 (de) 2002-11-07
NO1998003I1 (no) 1998-01-15
HK81097A (en) 1997-06-20
NO170487C (no) 1992-10-21
CA1308102C (en) 1992-09-29
US5004758A (en) 1991-04-02
KR890009934A (ko) 1989-08-05
GR3021990T3 (en) 1997-03-31
ATE143368T1 (de) 1996-10-15
PT89111A (pt) 1989-12-29
KR930009357B1 (ko) 1993-09-28
NO170487B (no) 1992-07-13
NZ227124A (en) 1991-12-23
FI885569L (fi) 1989-06-02
NL970017I2 (nl) 1997-09-01
IL88517A0 (en) 1989-06-30
DK663688A (da) 1989-06-02
CY2017A (en) 1998-02-20
AU612735B2 (en) 1991-07-18
CN1087637A (zh) 1994-06-08
NL970017I1 (nl) 1997-06-02
CN1083817A (zh) 1994-03-16
IL88517A (en) 1994-10-07
PT89111B (pt) 1994-01-31
JPH0633268B2 (ja) 1994-05-02
ES2094721T3 (es) 1997-02-01
FI89923B (fi) 1993-08-31
NO885352D0 (no) 1988-11-30
EP0321122A2 (en) 1989-06-21
FI89923C (fi) 1993-12-10

Similar Documents

Publication Publication Date Title
NO885352D0 (no) Vannloeselige camptothecin-analoger.
NO882608D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazolopyrideirer.
HUT53368A (en) Process for producing pyrazolo-pyridine derivatives and pharmaceutical compositions containing them
DK162519C (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne
AU6216886A (en) Substituted 2-cyano-2-phenyl ethyl-amine
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
NZ331256A (en) Benzo[c]quinolizine derivatives, their preparation and use as 5 alpha-reductases inhibitors
HU893127D0 (en) Process for the preparation of novel spiro-(imidazolidino-naphtaline) derivatives and pharmaceutical compositions containing such compounds as active ingredient
ATE38982T1 (de) Guanidinmethylcyclohexancarbonsaeure-derivate, verfahren zur herstellung und pharmazeutische mittel.
ATE30724T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten.
EP0302633A3 (en) Beta-lactam compound, process for preparing the same, intermediate for synthesis of the same and medicinal composition for bacterially infectious disease therapy containing the same
DE3665593D1 (en) Peptide immunostimulants
IT1205114B (it) 2-selenometil-1,4-diidropiridine,procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
GB1471546A (en) 1-acyl-4-substituted alkyl-piperazine or homopiperazine derivatives nad process for preparation thereof
NO167382C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-hydroxy-4-(substituerte alkenyl)cyklohexancarboxylsyrer.

Legal Events

Date Code Title Description
MK1K Patent expired

Name of requester: C/O ADVOKATFIRMAET SELMER DA